全覆盖准入政策？市场准入和 HTA 发展综述：第 5 部分。
Access in all areas? A round up of developments in market access and HTA: part 5.
机构信息
Lane Clark & Peacock LLP, London, W1U 1DQ, UK.
Centre for Pharmaceutical Medicine Research, King's College London, SE1 9NH, UK.
出版信息
J Comp Eff Res. 2024 Nov;13(11):e240179. doi: 10.57264/cer-2024-0179. Epub 2024 Oct 1.
Abstract
In this latest update, we explore the recent announcement by Canada's Drug Agency (CDA-AMC, formerly CADTH) on their pilot to include the societal perspective in the evaluation of certain new medicines; a recent Office of Health Economics (OHE) report on the evaluation of HTA agency methods over time; and publications examining the impact of Project Orbis on patient access to oncology treatments.
摘要
在最新的更新中，我们探讨了加拿大药品管理局（CDA-AMC，前身为 CADTH）最近宣布的一项试点计划，即将社会视角纳入某些新药评估中；最近卫生技术评估机构（HTA）方法评估的卫生经济办公室（OHE）报告；以及研究项目 Orbis 对肿瘤治疗患者获得治疗机会影响的出版物。
相似文献
1
Access in all areas? A round up of developments in market access and HTA: part 5.全覆盖准入政策？市场准入和 HTA 发展综述：第 5 部分。
J Comp Eff Res. 2024 Nov;13(11):e240179. doi: 10.57264/cer-2024-0179. Epub 2024 Oct 1.
2
Access in all areas? a round up of developments in market access and health technology assessment: part 4.所有领域都能准入吗？市场准入和卫生技术评估发展情况综述：第 4 部分。
J Comp Eff Res. 2024 Jun;13(6):e240060. doi: 10.57264/cer-2024-0060. Epub 2024 Apr 22.
3
Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis.在美国、加拿大、英国和苏格兰，通过项目观测网（Orbis）审查的 FDA 批准的癌症药物的临床获益、报销结果和价格：一项回顾性、比较分析。
Lancet Oncol. 2024 Aug;25(8):979-988. doi: 10.1016/S1470-2045(24)00286-9. Epub 2024 Jul 11.
4
Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.卫生技术评估机构对肿瘤治疗报销文件中提交的经济评估的评价：来自加拿大、英国和澳大利亚的证据。
Curr Oncol. 2022 Oct 13;29(10):7624-7636. doi: 10.3390/curroncol29100602.
5
Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations.肿瘤药物的卫生技术评估过程：加拿大药品和卫生技术局（CADTH）的变化对公共支付方报销建议的影响
Curr Oncol. 2022 Mar 1;29(3):1514-1526. doi: 10.3390/curroncol29030127.
6
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 6.我们准备好申请报销了吗？健康技术评估相关真实世界证据的进展综述：第6部分。
J Comp Eff Res. 2022 May;11(7):473-475. doi: 10.2217/cer-2022-0043. Epub 2022 Mar 9.
7
Access in all areas? A round up of developments in market access and health technology assessment: part 1.全覆盖准入政策？市场准入和卫生技术评估发展综述：第 1 部分。
J Comp Eff Res. 2023 Oct;12(10):e230129. doi: 10.57264/cer-2023-0129. Epub 2023 Aug 16.
8
Early access for innovative oncology medicines: a different story in each nation.创新肿瘤药物的早期准入：各国情况各异。
J Med Econ. 2023 Jan-Dec;26(1):944-953. doi: 10.1080/13696998.2023.2237336.
9
Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?加拿大是否正在朝着更灵活的监管审批和报销流程发展，为肿瘤药物的真实世界证据（RWE）赋予转变后的角色？
Curr Oncol. 2024 Sep 18;31(9):5599-5607. doi: 10.3390/curroncol31090414.
10
FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment.加拿大环境下恶性血液病和肿瘤学适应证的 FDA 加速批准。
Curr Oncol. 2022 Jan 18;29(2):402-410. doi: 10.3390/curroncol29020036.
引用本文的文献
1
Access in all areas? A roundup of developments in market access and health technology assessment: part 6.全面准入？市场准入与卫生技术评估进展综述：第6部分。
J Comp Eff Res. 2025 Mar;14(3):e240239. doi: 10.57264/cer-2024-0239. Epub 2025 Jan 10.
本文引用的文献
1
Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis.在美国、加拿大、英国和苏格兰，通过项目观测网（Orbis）审查的 FDA 批准的癌症药物的临床获益、报销结果和价格：一项回顾性、比较分析。
Lancet Oncol. 2024 Aug;25(8):979-988. doi: 10.1016/S1470-2045(24)00286-9. Epub 2024 Jul 11.
2
Quantifying the insurance value for rare diseases: Duchenne muscular dystrophy.量化罕见病的保险价值：杜氏肌营养不良症。
Am J Manag Care. 2024 Jul 1;30(7):e217-e222. doi: 10.37765/ajmc.2024.89584.
3
Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis.2020 年至 2022 年期间，瑞士监管机构参与奥比斯项目对提交空白、审查时间和药物批准决策的影响：一项比较分析。
Lancet Oncol. 2024 Jun;25(6):770-778. doi: 10.1016/S1470-2045(24)00158-X. Epub 2024 May 13.
4
It Is Time to Reconsider the 3% Discount Rate.是时候重新考虑 3%的贴现率了。
Value Health. 2024 May;27(5):578-584. doi: 10.1016/j.jval.2024.03.001. Epub 2024 Mar 9.
5
Valuing Alzheimer Disease Therapies-Considering Costs and Benefits Beyond the Patient.重视阿尔茨海默病治疗——考量患者之外的成本与效益
JAMA Netw Open. 2021 Oct 1;4(10):e2131913. doi: 10.1001/jamanetworkopen.2021.31913.
6
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?加拿大二线纳武利尤单抗治疗鳞状非小细胞肺癌患者的成本效益分析扩展影响的探索性病例研究：是否有影响？
Health Policy. 2018 Jun;122(6):607-613. doi: 10.1016/j.healthpol.2018.04.008. Epub 2018 Apr 26.
Zotero 插件